arrow
M

Markus Kraemer

european reference center for moyamoya angiopathy
H指数:35
被引数:4,372

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Outcome Predictors in Progressive Multifocal Leukoencephalopathy Associated With Multiple Sclerosis Treatments A Multicenter Cohort Study

多发性硬化治疗相关进行性多灶性脑白质病预后的预测因子:一项多中心队列研究

2026-05-010
PRE
Disease Characteristics and Treatments Associated with Outcome in Primary Angiitis of the Central Nervous System—A Multicenter Cohort Study in 163 Patients

中枢神经系统原发性血管炎的疾病特征与治疗及其与预后的关系——一项包含163例患者的多中心队列研究

2025-06-230
OAAI
Anti-VGLUT2 autoantibodies in neurological diseases

抗VGLUT2自身抗体在神经疾病中

2025-06-080
PRE
Worse recovery from acute attacks and faster disability accumulation highlights the unmet need for improved treatment in patients with late-onset neuromyelitis optica spectrum disorders (COPTER-LO study)

急性发作后恢复更差以及残疾累积更快,突显了晚期发作视神经脊髓炎谱系障碍(COPTER-LO研究)患者对改进治疗的未满足需求。

2025-04-110
PRE
Presentation and Outcome in S1P-RM and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
2024-09-010
OAAI
Broader anti-EBV TCR repertoire in multiple sclerosis: disease specificity and treatment modulation
BRAIN
IF11.7
2024-07-180
PRE
Recommendations for optimal interdisciplinary management and healthcare settings for patients with rare neurological diseases

针对罕见神经系统疾病患者的最佳跨学科管理和医疗机构的建议

2024-02-132
OAAI
Time to Disability Milestones and Annualized Relapse Rates in NMOSD and MOGAD
2024-01-1322
OAAI
Rare variants in ANO1, encoding a calcium-activated chloride channel, predispose to moyamoya disease
BRAIN
IF11.7
2023-05-3012
PRE
Effects of the COVID-19 Pandemic on Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Diseases COPANMO(G)-Study
2023-03-017
OAAI
Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders
2022-01-0182
OAAI